Emily Crossley
Amministratore Delegato presso Duchenne UK
Profilo
Emily Crossley is the founder of Duchenne UK, which is founded in 2012, where she currently holds the title of Joint Chief Executive Officer.
She is also currently a Director at Duchenne Research (UK) Investment Ltd.
Posizioni attive di Emily Crossley
| Società | Posizione | Inizio |
|---|---|---|
Duchenne UK
 Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Amministratore Delegato | 01/01/2012 |
Duchenne Research (UK) Investment Ltd.
 Duchenne Research (UK) Investment Ltd. BiotechnologyHealth Technology Duchenne Research (UK) Investment Ltd. is a biotechnology research and British experimental development company founded in 2014. The location of the private company is not specified. The company provides services in the field of biotechnology research and development. | Direttore/Membro del Consiglio | 05/01/2016 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Duchenne UK
Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Miscellaneous |
Duchenne Research (UK) Investment Ltd.
Duchenne Research (UK) Investment Ltd. BiotechnologyHealth Technology Duchenne Research (UK) Investment Ltd. is a biotechnology research and British experimental development company founded in 2014. The location of the private company is not specified. The company provides services in the field of biotechnology research and development. | Health Technology |
- Borsa valori
- Insiders
- Emily Crossley
